Eplerenone Versus PDT: Comparative Study by OCTA

Study Overview
=================
Brief Summary
-----------------
The study aims to analyze the changes in OCTA parameters and in choroidal thickness in patients affected by central serous chorioretinopathy treated by oral eplerenone and half-fluence photodynamic therapy.

Detailed Description
-----------------
Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by serous detachment due to the dilatation and hyperpermeability of choroidal vessels resulting in the accumulation of serous fluid between the neurosensory retina and the retinal pigment epithelium. Several studies reported the efficacy of half-fluence photodynamic therapy (PDT) and oral eplerenone in the CSC treatment inducing a reduction of the choroidal hyperpermeability and remodeling the choroidal vascularization. This retrospective study aims to perform a quantitative analysis of retinal and CC vessel density by OCTA at baseline, 3 and 6 months in patients underwent PDT and patients underwent eplerenone.

Official Title
-----------------
OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study

Conditions
-----------------
Central Serous Chorioretinopathy

Intervention / Treatment
-----------------
* Drug: Eplerenone
* Device: The patients underwent half fluence photodynamic therapy for 6 months


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 30 years diagnosis of central serous chorioretinopathy treatment-naïve with half-fluence photodynamic therapy or oral eplerenone absence of vitreoretinal and vascular retinal diseases Exclusion Criteria: age younger than 30 years absence of diagnosis of central serous chorioretinopathy previous treatment with half-fluence photodynamic therapy or oral eplerenone presence of concomitant vitreoretinal and vascular retinal diseases

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Half fluence photodynamic therapy<br>Patients with central serous chorioretinopathy, treated by half-fluence photodynamic therapy | Device: The patients underwent half fluence photodynamic therapy for 6 months<br>* Half fluence photodynamic therapy for 6 months<br>|
| Oral Eplerenone<br>Patients with central serous chorioretinopathy, treated by oral eplerenone | Drug: Eplerenone<br>* The patients underwent eplerenone treatment for 6 months<br>* Other names: Eplerenone in oral dose form;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Study of vessel density in retinal choriocapillaris networks, using OCTA, in patients underwent half fluence photodynamic therapy and oral eplerenone | To evaluate the role of optical coherence tomography angiography in predicting the changes of the vessel density of retinal and choriocapillaris vascular networks , comparing patients underwent half-fluence phodynamic therapy and patients with oral eplerenone. The vessel density are expressed as percentage | 6 months |